Fluvastatin: A review of its use in lipid disorders

Drugs

Volumn 57, Issue 4, 1999, Pages 583-606

  Langtry, Heather D ^a,b   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; COLESTYRAMINE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; RIFAMPICIN; SIMVASTATIN;

ABDOMINAL PAIN; ARTICLE; ATHEROGENESIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOMODULATION; INSOMNIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; META ANALYSIS; MYOPATHY; NAUSEA; ORAL DRUG ADMINISTRATION;

ANTILIPEMIC AGENTS; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INDOLES; RANDOMIZED CONTROLLED TRIALS;

EID: 0032891783     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957040-00009     Document Type: Article

References (107)

1. 1. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Overview and summary. Circulation 1994 Mar; 89: 1333-43, 1432-45
2. 2. Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994 Oct; 110: 121-61
3. 3. Stark RM. Review of the major intervention trials of lowering coronary artery disease risk through cholesterol reduction. Am J Cardiol 1996 Sep 26; 78 Suppl. 6A: 13-9
4. 4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov 19; 344: 1383-9
5. 5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996 Oct 3; 335 (14): 1001-9
6. 6. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997 Jan 16; 336 (3): 153-62
7. 7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995 Nov 16; 333 (20): 1301-7
8. 8. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998 May 27; 279 (20): 1615-22
9. 9. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 Nov 5; 339 (19): 1349-57
10. 10. Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs 1996 Mar; 51: 433-59
11. 11. Shiomi M, Ito T, Tsukada T, et al. Effect of fluvastatin sodium on the smooth muscle cells in atherosclerotic plaques: in vivo study using low-density lipoprotein receptor deficient Watanabe heritable hyperlipidemic (WHHL) rabbits. Arzneimittel Forschung 1998 Jun; 48: 680-5
12. 12. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996 Nov; 18: 669-75
13. 13. Corsini A, Raiteri M, Soma MR, et al. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995 Jul 13; 76: 21A-8A
14. 14. Corsini A, Bernini F, Quarato P, et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1996 Nov-Dec; 87: 458-68
15. 15. Bernini F, Didoni G, Bonfidini G, et al. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis 1993; 104: 19-26
16. 16. Mitani H, Bandoh T, Ishikawa J, et al. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br J Pharmacol 1996 Nov; 119: 1269-75
17. 17. Bellosta S, Via D, Canavest M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671-8
18. 18. Hussein O, Rosenblat M, Schlezinger S, et al. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 1997 Jul; 44: 77-83
19. 19. Aviram M, Hussein O, Rosenblat M, et al. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998 Jan; 31: 39-45
20. 20. Tan KCB, Janus ED, Lam KSL. Effects of fluvastatin on prothrombotic and fibrinolytic factors in non-insulin-dependent diabetic patients with dyslipidaemia [abstract]. Atherosclerosis 1998 Mar; 136 Suppl.: 55
21. 21. Bevilacqua M, Bettica P, Milani M, et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 1997 Jan 1; 79: 84-7
22. 22. Colli S, Eligini S, Lalli M, et al. Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997 Feb; 17: 265-72
23. 23. Leonhardt W, Kurktschiev T, Meissner D, et al. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals. Eur J Clin Pharmacol 1997 Sep; 53: 65-9
24. 24. Hussein O, Schlezinger S, Rosenblat M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997 Jan 3; 128: 11-8
25. 25. Guethlin M, Kasel AM, Coppenrath K, et al. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 1999; 9: 475-81
26. 26. Eichstädt H, Amthauer H, Jochens R, et al. Short-term fluvastatin therapy increases myocardial perfusion in patients with coronary artery disease [abstract]. Eur J Clin Invest 1996; 26 Suppl. 1: 3
27. 27. Sidhu P, Forbat S, Naoumova R, et al. Assessment of lipid-lowering therapy by non-invasive cardiovascular imaging [abstract]. Atherosclerosis 1997 Feb 10; 128: 261
28. 28. Schobel HP, Schmieder RE. Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin. Angiology 1998 Sep; 49 (9): 743-8
29. 29. Abetel G, Poget PN, Bonnabry JP. Antihypertensive effect of a cholesterol-lowering agent (fluvastatin): pilot study [in French]. Schweiz Med Wochenschr 1998 Feb 14; 128: 272-7
30. 30. John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized. placebo-controlled, double-blind study. Circulation 1998 Jul 21; 98: 211-6
31. 31. Rothe G, Elbracht R, Hauser I, et al. Relative decrease of cytotoxic T cells under fluvastatin treatment in kidney transplanted patients [abstract]. Atherosclerosis 1997 Oct; 134 (1-2): 282
32. 32. Rothe G, Stöhr J, Abletshauser C, et al. A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment [abstract]. Atherosclerosis 1997 1-2, Oct No.; 134: 235-6
33. 33. Madej A, Kalina Z, Okopién B, et al. The release of tumor necrosis factor-alpha by cultured macrophages from hyperlipidemic patients treated with fluvastatin [abstract]. Eur J Clin Pharmacol 1997; 52 Suppl.: 76
34. 34. Jokubaitis LA. Development and pharmacology of fluvastatin. Br J Clin Pract 1996 Jan Suppl. 77A: 11-5
35. 35. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet 1997 May; 32: 403-25
36. 36. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996 May; 50: 209-15
37. 37. Novartis. Lescol* data sheet. In: ABPI Compendium of data sheets and summaries of product characteristics. London: Datapharm Publications Ltd, 1998: 825-6
38. 38. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-5
39. 39. Torri A, Branchi A, Rovellini A, et al. Effect of fluvastatin on serum lipoproteins and glycemic control in hyperlipidemic patients with type II diabetes [abstract]. Atherosclerosis 1997 Oct; 134 (1-2): 384
40. 40. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of travastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993 Aug; 25 (4): 2732-4
41. 41. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311-21
42. 42. Arnadottir M, Eriksson L-O, Thysell H, et al. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65: 410-3
43. 43. Trilli LE, Kelley CL, Aspinall SL, et al. Potential interaction between warfarin and fluvastatin. Ann Pharmacother 1996 Dec; 30: 1399-402
44. 44. Kline SS, Harrell CC. Potential warfarin-fluvastatin interaction. Ann Pharmacother 1997 Jun; 31: 790
45. 45. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64: 58-65
46. 46. Aberg J, Eriksson U, Fager G. Effects of erythromycin on plasma fluvastatin levels: a pharmacokinetic study [abstract]. Atherosclerosis 1997 Oct; 134 (1-2): 118-9
47. 47. Kivistö KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998 Jul; 46: 49-53
48. 48. Meadowcroft AM, Williamson KM, Patterson JH, et al. The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics [abstract]. Clin Pharmacol Ther 1998 Feb; 63: 213
49. 49. McMillan K. Considerations in the formulary selection of hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health System Pharm 1996 Sep 15; 53: 2206-14
50. 50. Novartis. Data on file. Novartis Pharma AG, Basel, Switzerland
51. 51. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1998; 20: 58-69
52. 52. Widimsky J, Hulinsky V, Lanska V, et al. Czech and Slovak experience trial of fluvastatin in the treatment of hyperlipidemia [abstract]. 66th Congress of the European Atherosclerosis Society. 13-17 July, 1996. Florence, Italy
53. 53. Buzzi AP, Pastore MA, Argentine and Multicenter Evaluation Investigators. Argentine multicenter evaluation of fluvastatin in the treatment of patients with hypercholesterolemia. Curr Ther Res Clin Exp 1997 Dec; 58: 1013-28
54. 54. Beil S, Pfafferott C, Weber M. Fluvastatin lipid-lowering effect in routine practice conditions (FLIRT): results of a drug surveillance study. Clin Drug Invest 1997 Aug; 14: 146-53
55. 55. Weiss RJ. Fluvastatin titrate-to-goal clinical practice study. Am J Therap 1998; 5 (5): 281-5
56. 56. Sussekov A, Tvorogova M, Surkova E, et al. Fluvastatin in the treatment of NIDDM patients with hyperlipidaemia [abstract]. Atherosclerosis 1997 Oct; 134 (1-2): 317
57. 57. Ding PY-A, Sheu WH-H, Hu C-A, et al. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia [abstract]. Atherosclerosis 1998 Mar; 136 Suppl.: 44
58. 58. Exaire-Murad JE, Exaire-Rodriguez JE, Salgado-Loza JL. Fluvastatin in nephrotic syndrome hypercholesterolemia [abstract no. 209]. 66th Congress of the European Atherosclerosis Society. 13 Jul 1996. Florence, Italy
59. 59. Scanziani R, Dozio B, Bonforte G, et al. Fluvastatin and hyperlipidemia in peritoneal dialysis [abstract]. Nephrol Dial Transplant 1997 Sep; 12: A185
60. 60. Li PKT, Mak TWL, Chan TH, et al. Effect of fluvastatin on lipoprotein profiles in renal transplant patients with dyslipoproteinemia [abstract]. Kidney Int 1996 Oct; 50: 1409
61. 61. Holdaas H, Hartmann A, Stenstrm J, et al. Effect of incremental doses of fluvastatin in renal recipients treated with cyclosporine |abstract no. 215|. 66th Congress of the European Atherosclerosis Society. 13 Jul 1996. Florence, Italy
62. 62. Hadjigavriel M, Kyriakides G. Fluvastatin in renal transplantation. Transplant Proc 1997 Nov; 29: 3050
63. 63. Locsey L, Asztalos L, Kincses Z, et al. Fluvastatin (Lescol) treatment of hyperlipidaemia in patients with renal transplants. Int Urol Nephrol 1997; 29: 95-106
64. 64. Lal SM, Gupta N, Georgiev O, et al. Lipid-lowering effects of fluvastatin in renal transplant patients: a clinical observation. Int J Artif Organs 1997 Jan; 20: 18-21
65. 65. Stamm G. Lescol® (fluvastatin sodium) XU 62-320 oral capsules 20 mg and 40 mg: basic prescribing information. Data on file. 18 Dec 1998. Novartis Pharma AG, Basel, Switzerland
66. 66. New primary prevention trial for Lescol. Scrip 1998 Nov 6 (2385): 17
67. 67. La Belle P, Davidson M, Wilson H, et al. A comparison of lovastatin and fluvastatin |abstract no. 217|. 66th Congress of the European Atherosclerosis Society. 13 Jul 1996. Florence, Italy
68. 68. Schulte K-L, Beil S. Efficacy and tolerability of fluvastatin and simvastatin in hypercholesterolaemic patients: a double-blind, randomised, parallel-group comparison. Clin Drug Invest 1996 Sep; 12: 119-26
69. 69. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastalin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol 1998 Mar 1; 81: 582-7
70. 70. Schuster H, Berger J, Luft FC. Randomised, double-blind, parallel-group trial of atorvastatin and fluvastatin on plasma lipid levels in patients with untreated hyperlipidaemia. Br J Cardiol 1998 Nov; 5 (11): 597-602
71. 71. Pincus J. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study) [letter]. Am J Cardiol 1998 Aug 1; 82: 406-7
72. 72. Nash DT. Meeting national cholesterol education goals in clinical practice - a comparison of lovastatin and fluvastatin in primary prevention. Am J Cardiol 1996 Sep 26; 78 Suppl. 6A: 26-31
73. 73. Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients wilh documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998 Sep; 32; 665-72
74. 74. Hunninghake D, Bakker-Arkema RG, Wigand JP, et al. Treating to meet NECP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract 1998 Nov; 47 (5): 349-56
75. 75. Sasaki S, Nakagawa M, Nakata T, et al. Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol. Cardiology 1997 Mar-Apr; 88: 160-5
76. 76. Tomlinson B, Wong S-Y, Lan W, et al. Combination treatment with fluvastatin and gemfibrozil in resistant hyperlipidaemia |abstract|. Atherosclerosis 1998 Mar; 136 Suppl.: 56
77. 77. Farnier M, Leneveut-Ledoux L, French Fluvastatin Study Group. Long-term efficacy and safety of a combined fluvastatin-fenofibrate therapy in primary hypercholesterolemia (abstract). Atherosclerosis 1997 Oct; 134 (1-2): 123-4
78. 78. Lyakishev AA, Kozlov SG, Titov VN. Combined treatment with fluvastatin and fenofibrate in patients with severe hypercholesterolemia [abstract no. 218]. 66th Congress of the European Atherosclerosis Society. 13 Jul 1996. Florence, Italy
79. 79. Widimsky J, Hulinsky V, Balazovjech I, et al. Fluvastatin vs fluvastatin plus fenofibrate in CHD patients and combined hyperlipidemia [abstract]. Atherosclerosis 1997 1-2, Oct No.; 134: 63
80. 80. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [LCAS]). Am J Cardiol 1997 Aug 1; 80: 278-86
81. 81. West MS, Herd JA, Ballantyne CM, et al. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials 1996 Dec; 17: 550-83
82. 82. Riegger G, Abletshauser C, Ludwig M, et al. The effects of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis. In press
83. 83. Herd JA. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): lipid and metabolic factors related to atheroma and clinical events. Am J Med 1998 Jun 22; 104 Suppl.: 42-9
84. 84. Ballantyne CM, Herd JA, Schein JR, et al. Treatment of patients with mild to moderate hypercholesterolemia: Lipoprotein and Coronary Atherosclerosis Study (LCAS). Cardiovasc Rev Rep 1998 Jan; 19: 12-24
85. 85. Ballantyne CM, Schein JR, Herd JA. Influence of HDL-C on CHD progression and response to treatment. APOR Lipid Conference - Pharmacoeconomics and Outcomes Issues of Lipid Therapy 1997 Nov 6: Abstr. LC-1 (Poster)
86. 86. AHFS. Fluvastatin sodium. In: AHFS 98 Drug information. AHFS, 1998: 1443-5
87. 87. Fluvastatin and muscle disorders-a class effect. Aust Adv Drug React Bull 1996 Feb; 16: 3
88. 88. Lang JE, Wang P, Glueck CJ. Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism. Clin Chim Acta 1996 Oct 15; 254: 85-92
89. 89. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62: 28J-34J
90. 90. Jacobson TA. Preventing coronary heart disease in the managed care era: improving the cost effectiveness of lipid-lowering therapy with HMG-CoA reductase inhibitors. Am J Manage Care 1997 Sep: 3 Suppl. 1: 29-41
91. 91. Jacobson TA. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era. Am J Cardiol 1996 Sep 26; 78: 32-41
92. 92. Spearman ME, Summers K, Moore V, et al. Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization. Clin Ther 1997 May-Jun; 19: 582-602
93. 93. Levin L-Å, Schmidt A, Schulte K-L, et al. A comparison of clinical and pharmacoeconomic properties of fluvastatin and simvastatin in the management of primary hypercholesterolaemia. Br J Med Econ 1997; 11: 23-35
94. 94. Haasis R, Berger J, Andersson F, et al. A pharmacoeconomic evaluation of fluvastalin and lovastatin in primary hypercholesterolaemia. Br J Med Econ 1996; 10: 145-57
95. 95. Koren MJ, Smith DG, Hunninghake DB, et al. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients: a comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. PharmacoEconomics 1998 Jul; 14: 59-70
96. 96. Hilleman DE, Mohiuddin SM, Woodruff MP, et al. The CURVES trial: a pharmacoeconomic evaluation [abstract]. Pharmacotherapy 1997 Sep-Oct; 17: 1107-8
97. 97. Elliott WJ, Weir DR. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of myocardial infarction. APOR Lipid Conference - Pharmacoeconomics and Outcomes Issues of Lipid Therapy 1997 Nov 6: Abstr. LC-15
98. 98. Tong-Chung SM, Gilderman AM. Appropriateness and clinical outcomes with conversion to fluvastatin therapy in a managed care population. Poster presented at APOR Lipid Conference - Pharmacoeconomics and Outcomes Issues of Lipid Therapy; 1997 Nov; Orlando (FL)
99. 99. Algozzine TW, Whalen KM. Statin conversion initiative at a staff model health maintenance organization [abstract no. 95]. Pharmacotherapy 1998; 18 (5): 1152
100. 100. Moisan J, Vaillancourt R, Grégoire J-P, et al. Preferred HMG CoA reductase inhibitors: conversion and outcomes study [abstract no. LC-2]. APOR Lipid Conference - Pharmacoeconomic and Outcomes Issues of Lipid Therapy; 1997 Nov; Orlando (FL)
101. 101. Torborg SA, Stahl JG, Boreen DM, et al. Physician education to move lipotropic prescribing against the trends in the local market. APOR Lipid Conference - Pharmacoeconomics and Outcomes Issues of Lipid Therapy 1997 Nov 6: Abstr. LC-4
102. 102. Thomas M. Switching statins: can we do harm? N Z Med J 1998 Jan 23; 111: 18
103. 103. Thomas MC, Mann J, Williams S. The impact of reference pricing on clinical lipid control. N Z Med J 1998 Aug 14; 111: 292-4
104. 104. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998 Dec 5; 352 (9143): 1830
105. 105. Bennett W, McNee W. PHARMAC and statins. N Z Med J 1998 Nov 13: 439
106. 106. Frohlich J, Fodor G, McPherson R, et al. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and other dyslipidemias: interim report. Can J Cardiol 1998 Apr; 14 Suppl. A: 17-21
107. 107. Anonymous. The Lescol Intervention Prevention Study (LIPS): a randomised trial of the long-term effects of fluvastatin in patients with coronary heart disease after successful first transcatheter therapy. Novartis (Data on file)